ADC Therapeutics' Lonca, or loncastuximab tesirine, was granted priority review status by the FDA as a treatment for relapsed or refractory diffuse large B-cell lymphoma. The designation was based on results from a trial that linked the drug to a 48% overall response rate in previously treated DLBCL patients who had undergone an average of three systemic therapies.
ADC's loncastuximab tesirine gains priority review tag
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.